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Abstract
Respiratory complications before and after liver transplant are common, diverse, and potentially have a negative impact on patient
outcomes. In this review, we discuss the most frequent respiratory conditions that patients may develop in the perioperative
period. Their prevention and/or treatment may help to maximize the benefit these patients may derive from liver transplant. This
review examines diagnostic and therapeutic approaches to these complications for hepatologists, surgeons, and critical care
physicians.
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Introduction
Liver transplant (LT) is the definitive treatment for selected
patients with either complicated cirrhosis or acute liver failure
(ALF). Pulmonary complications before LT may have a nega-
tive impact on these patients’ outcomes after surgery or even
preclude such a procedure. Pulmonary complications early
after LT may further impair morbidity and mortality. However,
some of these respiratory complications may to some extent be
prevented or treated. Besides improving clinical outcomes,
such interventions may also optimize the use of health-
related resources and costs. With this review, we discuss the
most clinically relevant respiratory complications affecting
patients in the peri-LT period. In doing so, we hope to contrib-
ute to the multidisciplinary care such patients require at this
particular stage of their illness.
Respiratory Complications Before Liver
Transplant
Patients with cirrhosis and portal hypertension may develop
specific respiratory complications, including hepatic hydro-
thorax, hepatopulmonary syndrome, portopulmonary hyperten-
sion, and a-1-antitrypsin deficiency emphysema (AATD).
Albeit, not infrequent, hepatologists and intensivists need to
have a high index of suspicion to pursuit such diagnoses.
Furthermore, taking into account the impact of such respiratory
conditions on these patients’ prognosis, including access to LT,
it is fundamental to detect and treat them as early as possible. In
this section, we discuss not only these 4 noninfectious respira-
tory complications that may develop in patients with advanced
cirrhosis but also a common infectious respiratory condition
that may ensue in patients with either cirrhosis or ALF—
pneumonia.
Hepatic Hydrothorax
Definition and epidemiology. Hepatic Hydrothorax (HH) is
defined by a pleural effusion that develops in patients with
cirrhosis and/or portal hypertension in the absence of other
underlying thoracic (eg, pneumonia, heart failure, and malig-
nancy) or abdominal (eg, pancreatitis) etiologies. In a recent
cohort, among 763 patients with cirrhosis and ascites, 13% had
HH.1 In another cohort, among 862 patients with cirrhosis, 15%
developed HH.2
Pathophysiology. Hepatic Hydrothorax pathophysiology is not
completely understood. It has been proposed that HH develop-
ment resembles the mechanism of ascites accumulation in the
context of portal hypertension.3 The combination of intra-
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abdominal positive pressure and intrathoracic negative pres-
sure potentiates the movement of fluid from the peritoneal
cavity into the pleural space through diaphragmatic fenestra-
tions.4 These tissue defects, usually less than 1 cm in diameter,
are more frequent on the right side, in proximity with the liver,
as the left side of the diaphragm is more muscular and
thicker.5,6 While HH is more frequently (68%) right-sided, it
can be left-sided (13%) or bilateral (19%).1
Clinical presentation and diagnosis. The clinical presentation of
patients with HH varies widely, especially with the volume
and rate of pleural fluid and ascites accumulation. Therefore,
these patients may be asymptomatic, present dyspnea and
abdominal discomfort due to large volume ascites, or evolve
to respiratory failure.
The diagnosis of HH requires evidence of cirrhosis and
portal hypertension (clinical, biochemical, radiology, and/or
histopathology) and the exclusion of other causes of pleural
effusion. Using a chest X-ray (frontal and lateral), most pleural
effusions with >250 mL are identifiable.7 Bedside chest ultra-
sound or computed tomography (CT) scan may be needed to
diagnose smaller accumulations of fluid.8 Furthermore, CT
scan is more accurate in excluding other pulmonary patholo-
gies. A transthoracic echocardiogram (TTE) is often needed to
exclude cardiac pathology.
If feasible, an ultrasound-guided thoracentesis should be
performed for HH diagnosis. HH is usually a transudate
(pleural/serum total protein ratio <0.5 and/or pleural/serum
lactate dehydrogenase ratio <0.6) associated with portal hyper-
tension (serum/pleural albumin >1.1 g/dL). While uncompli-
cated HH has a polymorphonuclear cell count 250 cells/mL,
spontaneous bacterial empyema is defined by whether positive
pleural fluid culture and cell count >250 cells/mL or negative
pleural fluid culture and a cell count >500 cells/mL.9
Other pleural fluid tests that should be requested include pH,
amylase, triglycerides, adenosine deaminase, and cytology. A
complete septic screen is also mandatory, including sputum
(tracheal aspirate in ventilated patients), blood, ascites, and
urine. In a cohort of 120 patients with HH, 16 patients had
24 events of spontaneous bacterial pleuritis; 10 of those epi-
sodes had no concomitant spontaneous bacterial peritonitis
(SBP).9 The most frequent bacteria involved were Enterobac-
ter species (eg, Escherichia coli and Klebsiella pneumonia),
Streptococcus species, and Enterococcus species.9
Treatment and prognosis. The principles of HH treatment are
based on those of ascites.10 Sodium restriction (<2 g/d) and
diuretics (spironolactone up to 400 mg/d and furosemide up
to 160 mg/d) are usually the first line of treatment. The goal
would be to lose 0.5 kg/d to 1 kg/d while avoiding adverse
effects, especially acute kidney injury and electrolyte distur-
bances (eg, hyponatremia and hypokalemia).
Spontaneous bacterial pleuritis is treated empirically much
like SBP, usually with cefotaxime or ceftriaxone as first-line
antibiotics.10 However, the microbiological profile of each hos-
pital should be used for choosing the correct antibiotics.
Albumin cotherapy and long-term secondary prophylaxis with
antibiotics are not as well established as in SBP.
For symptomatic patients, drainage via ultrasound-guided
thoracentesis should be performed. While there is risk of pneu-
mothorax or hemothorax, the procedure is usually safe. If there
is concomitant large volume ascites, an ultrasound-guided
paracentesis could be attempted prior to the thoracentesis, as
this may help relieve patients’ symptoms. Chest tube place-
ment should be considered if there is pneumothorax, or pus
or blood is identified after the thoracentesis. The drainage of
large volumes of protein-rich pleural fluid with a chest tube in
situ may increase the risk of acute kidney injury and electrolyte
disturbances.11 Furthermore, it may be difficult to remove the
chest tube due to rapid pleural fluid reaccumulation.12 Despite
these concerns, the insertion of a pigtail catheter to drain the
hydrothorax has been attempted and proved reasonably effec-
tive and safe.13
For patients warranting HH drainage every 2 to 3 weeks,
despite sodium restriction and optimized diuretic therapy, other
treatment options should be considered.3 Transjugular intrahe-
patic portosystemic shunt (TIPS) has been used for HH
refractory to medical therapy. According to 1 meta-analysis,
post-TIPS response rate was 73% and 45-day mortality was
18%.14 Contraindications to the procedure may be age >70
years, hepatic encephalopathy, large portal vein thrombosis,
right-sided heart failure, elevated pulmonary arterial pressure,
and a model for end-stage liver disease (MELD) score >15.3,15
Video-assisted thoracoscopy with pleurodesis or surgical
closure of the diaphragm fenestrations has been studied in
small cohort studies. Despite reasonable response rates
reported, the complication rate, especially infection, is still of
concern.16,17 Therefore, these treatment options are to be con-
sidered mainly within an experimental context or as a last resort
measure, namely, for palliation.
Liver transplantation (LT) is the definitive treatment for
HH. Following diagnosis, patients with HH should be referred
to a LT center. There is lack of evidence regarding any waitlist
mortality excess due to HH; hence, there is no MELD excep-
tion points to apply. Outcomes post-LT have been reported as
similar to other transplanted patients with an 8-year survival
rate of 70%.18,19
Hepatopulmonary Syndrome
Definition and epidemiology. Hepatopulmonary syndrome (HPS)
is defined by an oxygenation defect characterized by intrapul-
monary vascular dilatation that develops in patients with cir-
rhosis and/or portal hypertension. Hepatopulmonary syndrome
may occur in patients with coexistent cardiopulmonary condi-
tions that further impair oxygenation. In a recent cohort, among
74 patients with cirrhosis, 23% had HPS.20 In another cohort,
among 316 patients with cirrhosis, 26% developed HPS.21
Pathophysiology. Hepatopulmonary syndrome results from
abnormal dilatation of pulmonary capillaries.22 Experimental
studies suggest that these vascular alterations derive from at
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least 2 mechanisms: local increase in nitric oxide production
due to endothelial stimulation by hepatic endothelin-1 or
monocyte activation by bacterial endotoxins; and angiogenesis
in which endothelial growth factor A and CX3CL1 factor seem
to be involved.23,24 This pulmonary vasodilation results in ven-
tilation–perfusion mismatch, which leads to hypoxemia.25
Clinical presentation and diagnosis. The clinical presentation of
patients with HPS varies from being asymptomatic to present
dyspnea or even progress to respiratory failure. While dyspnea
upon standing (platypnea) and hypoxemia exacerbated in the
upright position (orthodeoxia) are characteristic features, they
are present in <25% of patients.22
The diagnostic criteria of HPS are displayed in Table 1.25,26
An arterial blood gas is necessary to calculate the alveolar
arterial oxygen gradient. To confirm the pulmonary capillary
dilatation, a contrast-enhanced TTE is the most sensitive
test.22 Alternatively, a radionuclide lung perfusion scan using
technetium-labeled macroaggregated albumin (MAA) may be
used. This test is especially useful if there is coexistent HPS
and intrinsic lung disease with severe hypoxemia (arterial
oxygen pressure (PaO2) < 60 mm Hg), as MAA brain uptake
6% suggests HPS is the most important contributor to
hypoxemia.27
Treatment and prognosis. There is no established medical ther-
apy for HPS. Supplemental oxygen is used to avoid persistent
hypoxemia. Controlling other causes that may additionally
impair oxygenation (eg, hepatic hydrothorax, heart failure, and
chronic obstructive pulmonary disease) is also necessary.
While the severity of liver disease has not been associated
with the severity of hypoxemia, LT is the ultimate treatment for
HPS.26 Following diagnosis, patients with HPS should be
referred to a LT center. After LT, improvement in oxygenation
is expected in almost all patients, and outcomes have been
reported as similar to other transplanted patients with a
5-year survival rate of 76%.28,29 While lower pre-LT PaO2 has
not been associated with increased waitlist mortality, it has
been associated with worse post-LT outcomes.29 Although
controversial, according to the Organ Procurement and Trans-
plantation Network (OPTN) in the United States, patients with
severe HPS in the waitlist for LT are offered at inclusion an
exception MELD score of 22, and this is increased every 3
months if hypoxemia remains severe.26,29
Portopulmonary Hypertension
Definition and epidemiology. Portopulmonary hypertension
(POPH) is defined by pulmonary arterial hypertension associ-
ated with portal hypertension with or without cirrhosis.22 Car-
diopulmonary etiologies of pulmonary arterial hypertension
may coexist and need to be investigated. In a recent cohort,
among 1235 LT candidates, 5% had POPH.30
Pathophysiology. Pathophysiology of POPH is not fully under-
stood. Several factors have been associated with the arterial
occlusion (due to vasoconstriction, endothelial and smooth
muscle proliferation, in situ thrombosis, and plexogenic arter-
iopathy) that characterizes POPH: deficiency in endothelial
prostacyclin synthase resulting in platelet dysfunction and
increased level of endothelin 1; increased levels of estrogens
in females; and portosystemic shunts.22,31 This pulmonary
arterial hypertension results in ventilation–perfusion mismatch,
which leads to hypoxemia.25
Clinical presentation and diagnosis. The clinical presentation of
patients with POPH varies from being asymptomatic to present
dyspnea or even to develop respiratory failure. Exertional dys-
pnea is the most common symptom reported.22,31 Features of
right heart failure such as the following may be present in the
most severe cases: peripheral edema on clinical examination;
signs of right atrial enlargement, right ventricular hypertrophy,
right axis deviation, or right bundle branch block on the 12-lead
electrocardiogram, and increased right ventricular systolic
pressure (RVSP) on TTE.22,25 Being a noninvasive test, RVSP
evaluation has been proposed as the screening test for POPH
with levels 40 to 50 mm Hg being used to select patients for
right heart catheterization.22,31
Two hemodynamic patterns in patients with portal hyperten-
sion may be confounded with POPH, the hyperdynamic circu-
lation of cirrhosis or fluid overload, both are with increased
mean pulmonary artery pressure (mPAP) but normal pulmon-
ary vascular resistance (PVR). Therefore, the diagnostic cri-
teria of POPH depend on right heart catheterization that is
displayed in Table 2.22,31,32
Treatment and prognosis. Medical therapy for POPH has relied
on 3 different classes of vasodilators, based on their use in
primary pulmonary hypertension. Prostacyclin analogs, the
most common being epoprostenol (intravenous administra-
tion), have been associated with improved mPAP and
PVR.33,34 Endothelin receptor antagonists, the most frequently
Table 1. Diagnostic Criteria and Severity Classification of Hepato-
pulmonay Syndrome.
Hypoxemia cause and severity of disease
Alveolar arterial oxygen gradient >15 mm Hg (>20 mm Hg if age
>64 years)a
Mild: PaO2 80 mm Hg
Moderate: PaO2 60-79 mm Hg
Severe: PaO2 50-59 mm Hg
Very severe: PaO2 <50 mm Hg
Pulmonary capillary dilatation confirmation
Contrast-enhanced transthoracic echocardiogram: injected air
bubbles appear delayed >3 cardiac cycles in the left cardiac
chambers or Radionuclide lung perfusion scan using technetium-
labeled macroaggregated albumin: injected particles are detected
in post-pulmonary capillaries (eg, brain, spleen, or kidneys)
Abbreviations: FiO2, oxygen inspired fraction; PaCO2, carbon dioxide arterial
pressure; PAO2, alveolar oxygen pressure; PaO2, arterial oxygen pressure;
Patm, atmospheric pressure; PH2O, atmospheric water pressure.
aPAO2-PaO2 ¼ [FiO2(Patm-PH2O)-PaCO2/0.8]-PaO2.
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used being bosentan or ambrisentan (oral administration), have
been associated with improved lung hemodynamics.35,36
This class of drugs may be associated with hepatotoxicity and
thus warrant monitoring of liver blood tests. Finally,
phosphodiesterase-5 inhibitors, the most common being silde-
nafil, tadalafil, or vardenafil (oral administration), have also
shown to benefit lung hemodynamics.37,38 Despite improving
lung hemodynamics and early exercise capacity, these medica-
tions are yet to prove their impact in long-term survival.
Patients with POPH without treatment had a 5-year survival
of 14%.37 Survival post-LT worsens with pre-LT disease sever-
ity with perioperative mortality for patients with mPAP >50
mm Hg reaching 100%.38 Therefore, according to the OPTN in
the United States, patients with baseline moderate POPH who
respond to vasodilator therapy (mPAP <35 mm Hg and PVR
<400dyn.s1 cm5) and have normal right ventricular function
in the waitlist for LT are offered at inclusion an exception
MELD score of 22, and this is increased every 3 months if
these criteria are still true.22,25 Following LT, vasodilator ther-
apy is often continued and 3-year survival has been reported as
77%.39,40
a-1-Antitrypsin Deficiency Emphysema
Definition and epidemiology. a-1-antitrypsin deficiency emphy-
sema is an autosomal-dominant disease characterized by
reduced production of the serine protease inhibitor a-1-
antitrypsin (AAT). The most common deficient allele is the Z
allele with a prevalence of 2% to 3% in the United States; the
most frequent clinically relevant phenotype is the ZZ with a
prevalence of 0.05% in the United States.41 a-1-Antitrypsin
deficiency emphysema accounts for 1.1% of adult LTs and
3.5% of paediatric LTs in the United States.42
Pathophysiology. In the lungs, AAT functions normally by inac-
tivating neutrophil elastase. In AATD, uninhibited neutrophil
elastase activity causes destruction of alveolar elastin which
leads to panacinar emphysema.43 In the liver, ZZ AATD is
characterized by abnormal folding and polymerization of the
ZZ protein. The accumulation of this protein in the hepatocytes
causes cell death, fibrosis, and eventually cirrhosis.44
Clinical presentation and diagnosis. Recognizing patients with
AATD is often difficult, as both lung and liver diseases have
clinical and laboratory presentations similar to other etiologies.
Suspicion should prompt diagnostic testing if 1 or more of the
following features are present: neonates, children, or adults
with unexplained liver disease, adults with obstructive pulmon-
ary syndrome incompletely reversible with optimized bronch-
odilators, adults with necrotizing panniculitis, or adults with
c-ANCA positive vasculitis.45 In Z allele heterozygotes with
active liver or vasculitic disease, the plasma AAT level may be
normal; therefore, serum phenotyping by isoelectric focusing is
the gold standard for diagnosing AATD.45
Treatment and prognosis. The medical therapy for AATD relies
generally on oxygen support, bronchodilators, and eventually
noninvasive ventilation (NIV). Specific augmentation therapy
with a-1-antiprotease (intravenous administration) may be
beneficial in moderate lung disease (forced expiratory volume
at 1 second 35%-60%) but not in liver disease.46 Liver trans-
plant and/or lung transplantation (LUT) are the ultimate treat-
ments for AATD. Five-year post LT (ZZ homozygotes) and
LUT survival rates have been reported as 80% and 38%,
respectively.44,47
Pneumonia
Definition and epidemiology. Pneumonia is an infection of the
lungs. In patients with cirrhosis, it is usually the third most
common cause of infection, following SBP and urinary tract
infection (UTI).48 In a recent cohort, among 946 patients with
cirrhosis admitted to hospital, 46 (4.9%) had pneumonia.49 In
another cohort, among 377 patients with cirrhosis admitted to
intensive care unit (ICU), 37 (9.8%) were diagnosed with pneu-
monia.50 In patients with ALF, it is the most common infection.
In an older cohort, among 50 patients with ALF admitted to
ICU, 23 (46.0%) had pneumonia.51
Pathophysiology. In patients with cirrhosis, the interplay of sev-
eral nonclinical and clinical factors increases the risk of infec-
tion: quantitative and qualitative alterations in gut microbiota,
increased permeability of the intestinal barrier, cirrhosis-
related immunodeficiency, genetic predisposition to infection,
low protein content in ascites, variceal bleeding, and poor liver
function.48 In patients with ALF, the inflammatory mediators
released from the injured liver into the circulation may impair
function of monocytes and increase the risk of infection.52
Clinical presentation and diagnosis. The clinical presentation of
patients with pneumonia frequently includes dyspnea and
fever. In one of the cohorts mentioned, among the 37 patients
with cirrhosis and pneumonia admitted to ICU, 16 (43.2%)
required invasive mechanical ventilation (IMV) on admis-
sion.50 In another cohort mentioned, among the 23 patients
with ALF and pneumonia admitted to ICU, 21 (91.3%)
required IMV during ICU stay.51
The final diagnosis of pneumonia encompasses clinical, bio-
chemical, microbiological, and radiological features. A com-
plete septic screen is mandatory, including sputum (tracheal
aspirate or even broncoalveolar lavage in ventilated patients),
Table 2. Diagnostic Criteria and Severity Classification of Portopul-
monay Hypertension.
Right heart catheterization and severity of disease
Mean pulmonary artery pressure >25mmHg
Mild: 25 mm Hg and <35 mm Hg
Moderate: 35 mm Hg and <45mmHg
Severe: 45mmHg
Pulmonary artery occlusion pressure <15mmHg
Pulmonary vascular resistance >240dyn.s-1.cm-5
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blood, ascites, and urine. In the cohorts including patients
with cirrhosis mentioned, the most common pathogens found
were as follows: (1) for community-acquired pneumonia,
Escherichia coli, Streptococcus pneumoniae, and Staphylo-
coccus aureus and (2) for hospital-acquired or nosocomial
pneumonia, P aeruginosa, Enterobacter species, and S
aureus.49,50 In the cohort including patients with ALF
mentioned, the most frequent bacteria isolated were S aureus,
P aeruginosa, and Acinetobacter calcoaceticus.51 Multiresis-
tant bacteria prevalence has been growing overtime most
likely in association with the more frequent use of prophy-
lactic antibiotics (eg, SBP) and need for invasive procedures
and hospital contacts.48
Treatment and prognosis. The medical therapy for pneumonia
relies initially on oxygen support and empirical or, if possible,
adjusted antibiotics. The role of prophylactic antibiotics for
pneumonia in cirrhosis or ALF has not been properly estab-
lished.48,53 The microbiological profile of each hospital will be
fundamental for choosing the correct antibiotics.
In 1 recent cohort, the 30-day post hospital admission mor-
tality rate of patients with cirrhosis and pneumonia (32.0%)
was significantly worse than the ones who had other infec-
tions, incuding SBP (19.7%), UTI (14.6%), and other types
(13.8%).54 In another cohort, among patients with cirrhosis
admitted to ICU with need for IMV, ICU mortality rate was
65.9%.55 Furthermore, infection and longer ventilator-
dependency were significantly associated with worse mortal-
ity rates.
The prognosis of patients with cirrhosis or ALF and pneu-
monia definitively worsens if acute respiratory distress syn-
drome and/or septic shock ensues.52,55 In this context, organ
support measures in the ICU are crucial. Although patients may
need lung-protective ventilatory strategies (eg, low tidal vol-
ume and permissive hypercapnia, and high positive end-
expiratory pressure), hemodynamic instability often requires
resuscitation with fluids and vasopressors. Invasive monitoring
of the hemodynamic status (eg, pulse contour cardiac output
[PiCCO] studies) is warranted to avoid further impairment of
the oxygenation capacity due to intrathoracic fluid accumula-
tion.52,56 In the context of septic shock, initiation of antibiotics
within 1 hour of diagnosis has been shown to reduce early
mortality.55,57
Uncontrolled sepsis may lead to delisting patients from the
LT waitlist. In 1 recent cohort, among 136 patients with cir-
rhosis admitted to hospital, 57 (41.9%) were delisted or died
within 6 months.58 Among this subgroup of patients, 23
(40.4%) had respiratory failure during hospital stay, one of the
most frequent organ failures. Furthermore, infection during the
initial hospital stay meant a 42% increase in risk of delisting or
death within 6 months. Therefore, preventive measures to
decrease risk of nosocomial infection, frequent septic screen,
and timely diagnosis and treatment of pneumonia in patients
with cirrhosis or ALF seem to be of paramount importance.
Early Respiratory Complications After
Liver Transplant
Patients who undergo LT frequently develop respiratory com-
plications, including pulmonary edema, pleural effusion,
atelectasis, pneumonia, and transfusion-related acute lung
injury (TRALI). While some of these events may present
entirely as postoperative complications, frequently there are
pre (eg, liver, heart, kidney functions, smoking, and nutritional
status) and/or intraoperative (eg, cold and warm ischemia times
and transfusion of blood products) factors associated with their
occurrence.59 Given their potentially negative impact on
patient morbidity and mortality, timely identification and treat-
ment are important.
Pulmonary Edema, Pleural Effusion, and Atelectasis
Definition and epidemiology. While pulmonary edema is the
accumulation of fluid in the lung interstitium and alveoli,
pleural effusion is the accumulation of fluid in the pleural
cavity. Atelectasis occurs when there is loss of volume in a
pulmonary anatomical region. In a recent cohort, among 90
patients who underwent LT, 16 (17.8%) had pulmonary
edema during ICU stay.60 In another cohort, among 187
patients who had LT, 70 (37.4%) developed pleural effusion
up to 48 hours following surgery.61 In a different cohort,
among 204 patients who underwent LT, 131 (64.3%) experi-
enced atelectasis within 1 week post LT.62
Pathophysiology. Pulmonary edema may be driven by increased
hydrostatic pressure (eg, fluid overload and heart failure) or
wall permeability (eg, septic shock and liver failure) in pul-
monary capillaries.63 Pleural effusion is often a transudate (eg,
fluid overload, heart failure, residual portal hypertension) but
may present as an exudate (eg, pneumonia).64 Atelectasis most
frequently may be due to airway obstruction (eg, respiratory
secretions impaction) or external compression of the lung (eg,
pleural effusion and pneumothorax).62 Additionally, reduced
chest movements due to postoperative pain or iatrogenic dia-
phragmatic dysfunction may lead to atelectasis.65
Clinical presentation and diagnosis. Patients with pulmonary
edema, pleural effusion, or atelectasis may be asymptomatic
or progressively develop dyspnea, with some of them evolving
to respiratory failure. In one of the cohorts mentioned, among
187 patients who had LT, 64 (34.2%) developed respiratory
failure, with 36 of those (56.3%) presenting more than 1 under-
lying respiratory complication (infectious or not).61 The con-
sequences on oxygenation capacity largely depend on the
severity and extent of each condition, with likely symptomatic
examples being extensive alveolar edema, large bilateral
pleural effusions, or complete lung collapse.
The diagnosis of these pulmonary complications is usually
confirmed with a chest X-ray (frontal and lateral).7 If diagnos-
tic doubts persist, a CT scan may be required.8 The differential
diagnosis of pulmonary edema often requires a TTE to exclude
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cardiac pathology and that of pleural effusion depends on
ultrasound-guided thoracentesis with pleural fluid analysis (see
details in HH section). A complete septic screen is also man-
datory, including sputum (tracheal aspirate in ventilated
patients), blood, ascites (if still present), and urine.
Treatment and prognosis. The medical therapy of pulmonary
edema and pleural effusion generally includes oxygen support
and diuretics, but patients not responsive to these measures
may require NIV. For atelectasis, the control of its underlying
cause is of paramount importance; for example, to avoid
respiratory secretions impaction, good bronchial toilette with
judicious use of sedatives, regular aspirations, or bronchoscopy
at times is helpful; to reverse a clinically significant pneu-
mothorax (symptoms and thickness >1 cm), a pleural drain is
warranted.
There is lack of studies evaluating the individual impact of
pulmonary edema, pleural effusion, and atelectasis on the prog-
nosis of patients who underwent LT. However, in one of the
cohorts mentioned, pulmonary edema in this context was asso-
ciated with longer ventilator-dependency and ICU stay.63
Pneumonia
Definition and epidemiology. The definition of pneumonia has
been presented in the previous Pneumonia section. In a
recent cohort, among 148 patients who underwent LT, 23
(15.5%) developed hospital-acquired pneumonia in the
ICU.66 In another cohort, among 228 patients who had
LT, 19 (8.3%) were diagnosed with hospital-acquired pneu-
monia in the ICU.67
Pathophysiology. Liver transplant recipients accumulate risk fac-
tors for pneumonia after transplant, for example, older age,
cirrhosis, higher MELD score, lower platelet count, restrictive
lung pattern, higher number of units of blood products trans-
fused during surgery, longer ventilator dependency, iatrogenic
atelectasis (see Pulmonary edema, pleural effusion, and atelec-
tasis section), and immunosuppression.65,68
Clinical presentation and diagnosis. The clinical presentation and
diagnosis of pneumonia have been described in the previous
Pneumonia section. In one of the cohorts mentioned, among 23
patients with pneumonia, 22 (95.7%) required IMV (14 were
already ventilated at the time of diagnosis, whereas 8 were
breathing spontaneously).66
In one of the cohorts mentioned, the most common patho-
gens found were as follows: Hemophilus influenzae, P aerugi-
nosa, and S aureus.66 In another cohort mentioned, the most
common bacteria isolated were as follows: P aeruginosa, S
aureus, and other Enterobacter species.68
Treatment and prognosis. Treatment of pneumonia has been dis-
cussed in the previous Pneumonia section. In one of the cohorts
mentioned, among 23 patients with pneumonia, 4 (17.4%) died
while in the ICU.66 In another cohort mentioned, pneumonia
was associated with longer ICU stay and higher hospital mor-
tality.68 Furthermore, pneumonia has also been identified as the
major cause for ICU readmission within the hospital stay fol-
lowing LT.65
Transfusion-Related Acute Lung Injury
Definition and epidemiology. Transfusion-related acute lung
injury (ALI) is defined as the acute lung injury that develops
up to 6 hours following transfusion of 1 or more units of blood
or blood products.69 In a recent cohort, among 632 patients who
underwent LT, 9 (1.4%) had hypoxemia compatible with
TRALI during surgery.70
Pathophysiology. The pathophysiology of TRALI has been
described by the 2 hit theory: (1) The first insult consists of
priming and adherence of neutrophils to the pulmonary
endothelium; and (2) the second insult includes activation of
these primed neutrophils, resulting in the release of reactive
oxygen species that cause capillary leak and pulmonary
edema.71 Risk factors for TRALI include the following: alco-
holism, smoking, liver surgery, shock, positive fluid balance,
higher peak airway pressure on the ventilator, higher interleu-
kin 8 level, transfusion of blood or blood products from female
donors, and higher volumes of HLA class II antibody or antihu-
man neutrophil antigen.72
Clinical presentation and diagnosis. Transfusion-related ALI
should be suspected and excluded in all cases of dyspnea and
hypoxemia (especially with respiratory failure, that is, PaO2/
inspired oxygen fraction (FiO2) ratio <300 mm Hg) developing
up to 6 hours following transfusion of any amount of blood or
blood products.
Aspiration of undiluted fluid from the tracheal tube may
help to establish the nature of the ongoing pulmonary edema:
increased capillary hydrostatic pressure if the tracheal fluid–
plasma protein ratio is <0.65 or wall permeability (as in
TRALI) if >0.75.71 PiCCO studies may also assist with such
differentiation. The confirmation of TRALI diagnosis requires
investigating the donor and recipient for passively transfused
antibodies.71,72
Treatment and prognosis. The treatment of TRALI is fundamen-
tally supportive. Lung-protective ventilatory strategies (see
Pneumonia section) are recommended as in ALI from other
causes. If patients develop hemodynamic instability, vasopres-
sors should be started and invasive hemodynamic monitoring
(eg, PiCCO studies) is often helpful to help manage fluid bal-
ance. An ETT to exclude cardiac pathology and a full septic
screen (see Pneumonia section) to exclude sepsis are warranted
in this context.
TRALI is usually a self-limited condition, and thus its prog-
nosis is often better than ALI from other etiologies.71 In a
recent cohort including general critically ill patients, among
89 patients with TRALI, 37 were breathing spontaneously
before diagnosis and from those 29 (78.4%) required IMV;
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also, 53 were independent of vasopressors before diagnosis and
from those 13 (24.5%) ended up on vasopressors.73 In compar-
ison to controls, patients with TRALI had longer ventilator
dependency and ICU stay. Of the 89 patients with TRALI,
15 (16.9%) died during hospital stay. In another cohort men-
tioned, among 9 patients with TRALI after LT, one (11.1%)
died postoperatively.
Transfusion-related ALI is not easy to prevent, but some
strategies may be worthwhile to consider; for example, under-
stand patient-specific clinical risk factors for TRALI, optimize
patients pre-LT in terms of hemoglobin, platelet count, and
clotting factors, titrate transfusions of blood and blood products
to necessary targets during peri-LT period, and discuss the
preferential use of blood from male donors.71
Conclusions
Respiratory complications before and after LT are common and
potentially can have a significant impact on posttransplant out-
comes. Therefore, clinicians should be aware of their specifi-
cities, display a high index of suspicion, and institute therapy in
a timely fashion so transplant recipients can succeed post-LT.
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19. Sersté T, Moreno C, Francoz C, et al. The impact of preoperative
hepatic hydrothorax on the outcome of adult liver transplantation.
Eur J Gastroenterol Hepatol. 2010;22(2):207-212.
20. Voiosu AM, Daha IC, Voiosu TA, et al. Prevalence and impact on
survival of hepatopulmonary syndrome and cirrhotic cardiomyo-
pathy in a cohort of cirrhotic patients. Liver Int. 2015;35(12):
2547-2555.
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